07:41 AM EDT, 07/28/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday that the US Food and Drug Administration has approved Skytrofa for the treatment of growth hormone deficiency or GHD in adult patients.

The company said the approval was based on the results of a phase 3 trial that compared the product with weekly placebo and daily somatropin in adults with GHD.

Ascendis said it plans to start a basket trial for other potential indications in Q4.

Shares of Ascendis Pharma ( ASND ) were up more than 1% in recent premarket activity Monday.